Trending...
- Boston: Mayor Wu Announces Applications Open for Spooky Streets Grant
- SmartBear to Host Virtual and Worldwide Events
- Major Release of Veeva Site Connect Streamlines Clinical Trial Execution for Sites and Sponsors
~ PhenomeX Inc., a functional cell biology company listed on the Nasdaq (CELL), has announced that it will be showcasing its latest optofluidic and proteomic technologies at two upcoming cell biology conferences.
At the Discovery on Target 2023 conference, held from September 25-27 in Boston, Genovac, a long-standing customer of PhenomeX and super user of the Beacon optofluidic technology, will lead a presentation featuring PhenomeX's Beacon platform. The presentation is entitled "Enhance and Expand Anti-ID Antibody Diversity and Affinity Through Genetic Immunization" and will be delivered by Andreas Weise, senior account manager at Genovac.
The Annual Festival of Biologics Basel Conference & Exhibition will also feature PhenomeX's optofluidic and proteomic technologies in booth #910. Jonathan Didier, senior field applications scientist at PhenomeX, will present "Rapid Discovery of Clinically Relevant Antibodies using the PhenomeX Beacon" as part of the Cell Culture & Upstream Processing conference track. Additionally, a poster presentation entitled "Rapid Discovery of Functional Human Memory B Cell-Derived Antibodies for SARS-CoV-2 Using the Beacon Optofluidic System" will be featured.
More on Boston Chron
PhenomeX is dedicated to advancing human health through its unique suite of high-throughput tools and services that offer unparalleled resolution and speed to accelerate discoveries that can profoundly improve the prevention and treatment of disease. Its award-winning platforms are used by researchers across the globe, including those at the top 15 global pharmaceutical companies and approximately 85% of leading U.S. comprehensive cancer centers. The company is also in the process of changing its name; all inquiries regarding Phenomenex, Inc. should be directed to their website.
At the Discovery on Target 2023 conference, held from September 25-27 in Boston, Genovac, a long-standing customer of PhenomeX and super user of the Beacon optofluidic technology, will lead a presentation featuring PhenomeX's Beacon platform. The presentation is entitled "Enhance and Expand Anti-ID Antibody Diversity and Affinity Through Genetic Immunization" and will be delivered by Andreas Weise, senior account manager at Genovac.
The Annual Festival of Biologics Basel Conference & Exhibition will also feature PhenomeX's optofluidic and proteomic technologies in booth #910. Jonathan Didier, senior field applications scientist at PhenomeX, will present "Rapid Discovery of Clinically Relevant Antibodies using the PhenomeX Beacon" as part of the Cell Culture & Upstream Processing conference track. Additionally, a poster presentation entitled "Rapid Discovery of Functional Human Memory B Cell-Derived Antibodies for SARS-CoV-2 Using the Beacon Optofluidic System" will be featured.
More on Boston Chron
- Anna DeVeaux and Bejan Mahmud Married in Boston
- Max Medeiros And Po-Hua Yi Married In Boston
- Vimaan Named in the Gartner® Hype Cycle™ Reports, 2024 for Autonomous Data Collection and Inspection
- Vantiva Unveils ONYX, its latest Smart Media Device with Advanced AI Capabilities at IBC 2024
- Boston Institute of Biotechnology & BiBo Pharma CEO Wins 2024 Global Biologics CDMO Technology Leadership Award
PhenomeX is dedicated to advancing human health through its unique suite of high-throughput tools and services that offer unparalleled resolution and speed to accelerate discoveries that can profoundly improve the prevention and treatment of disease. Its award-winning platforms are used by researchers across the globe, including those at the top 15 global pharmaceutical companies and approximately 85% of leading U.S. comprehensive cancer centers. The company is also in the process of changing its name; all inquiries regarding Phenomenex, Inc. should be directed to their website.
Filed Under: Business
0 Comments
Latest on Boston Chron
- Policy vs Politics Rebrands to Everything Policy: A New Era of Facts-first Policy Content
- GitKraken Launches DevEx Advance Partner Program to Help Atlassian Solution Partners Elevate Their Clients' Developer & DevOps Team Productivity
- Phinge's Plan to Save Free Speech and Give Everyone the Right to Personal Privacy and Ownership and Monetization of Their Online Data and Content
- The Royalty Network and CEO Frank Liwall Appoint Daniel Abowd as New President & General Counsel
- L2 Aviation Announces Strategic Growth Investment from Argentum
- African-American Marketing Association Launches Business of Marketing Bootcamp™ for Small Businesses
- WOHLER Announces its NEW iAM1-MIX8 Next Generation MIX Series Solution @ IBC 2024
- Inaugural Tough Tech Week in Boston Will Gather Inventors, Investors, and Innovators for Five Days of Collaboration and Connection
- The World's No.1 Superstar Dies After Choking on a French Fry
- Award-winning and Renowned Voice Actor Nancy Cartwright to Deliver Keynote at the That's Voiceover Career Expo 2024 in Los Angeles
- "Army of Liars" Exposes How Social Media Profits from Disinformation
- Cerity Partners Appoints Todd Cassler as First-Ever Chief Growth Officer
- Vantiva Demonstrates its Vision of the Connected Home of the Future with New Lineup of AI-Powered CPE at IBC 2024
- ApostilleDepot.com Expands Services to Offer Comprehensive Apostille & Document Legalization Solutions in Massachusetts and New Hampshire
- Challenge Arcade's World Record Weekend 2024
- Empowering Educators with AI: Goosechase and DIGITAL Partner for the Future of Interactive Experiences
- Join Us at the 136th Canton Fair from October 15th to 19th, 2024!
- Legendary Aviation Coffee Company Celebrates 2100% Growth with Exceptional Single-Origin Air-Roasted Coffee
- General Vincent Brooks (RET) Joins BEYA Stars and Stripes Committee as a Founder, Following 20 Years of Service by General Johnnie Wilson (RET)
- SafeTea Launches App to Safeguard Women